Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
1.8000 -0.0300 (-1.64%) 14:34 ET [NYSE]
1.7900 x 205 1.8000 x 200
Realtime by (Cboe BZX)
1.7900 x 205 1.8000 x 200
Realtime - - (-) -
Quote Overview for Thu, Mar 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.8000
Day High
1.8400
Open 1.8300
Previous Close 1.8300 1.8300
Volume 57,232 57,232
Avg Vol 368,071 368,071
Stochastic %K 63.98% 63.98%
Weighted Alpha -83.17 -83.17
5-Day Change +0.1500 (+9.09%) +0.1500 (+9.09%)
52-Week Range 1.5250 - 20.0000 1.5250 - 20.0000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,052
  • Shares Outstanding, K 14,236
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,200 K
  • EBIT $ -30 M
  • EBITDA $ -30 M
  • 60-Month Beta 1.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.29

Options Overview Details

View History
  • Implied Volatility 529.91% ( +285.69%)
  • Historical Volatility 85.67%
  • IV Percentile 95%
  • IV Rank 36.72%
  • IV High 1,372.26% on 02/12/25
  • IV Low 41.03% on 09/27/24
  • Put/Call Vol Ratio 0.36
  • Today's Volume 38
  • Volume Avg (30-Day) 192
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 13,143
  • Open Int (30-Day) 14,345

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.38
  • Number of Estimates 1
  • High Estimate -0.38
  • Low Estimate -0.38
  • Prior Year -1.09
  • Growth Rate Est. (year over year) +65.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5250 +18.03%
on 03/11/25
Period Open: 2.2300
2.2687 -20.66%
on 02/21/25
-0.4300 (-19.28%)
since 02/20/25
3-Month
1.5250 +18.03%
on 03/11/25
Period Open: 4.3700
5.6000 -67.86%
on 01/03/25
-2.5700 (-58.81%)
since 12/20/24
52-Week
1.5250 +18.03%
on 03/11/25
Period Open: 11.1000
20.0000 -91.00%
on 04/29/24
-9.3000 (-83.78%)
since 03/20/24

Most Recent Stories

More News
Annovis Bio (NYSE: ANVS) to Present at Alzheimer’s & Parkinson’s Drug Development Summit

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, will participate in the 13th Alzheimer’s & Parkinson’s Drug Development Summit from March...

ANVS : 1.8000 (-1.64%)
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

ANVS : 1.8000 (-1.64%)
Annovis Bio (NYSE: ANVS) to Host Patient Forum on Alzheimer’s and Parkinson’s Trials

Annovis Bio (NYSE: ANVS) will host a live webcast on Feb. 27, 2025, at 4:30 p.m. EST, where CEO Maria Maccecchini, Ph.D., will answer questions from patients, caregivers, and families regarding the company’s...

ANVS : 1.8000 (-1.64%)
Annovis to Host Patients’ Live Forum on February 27, 2025

ANVS : 1.8000 (-1.64%)
Annovis Bio (NYSE: ANVS) CEO to Present at Oppenheimer Healthcare Conference

Annovis Bio (NYSE: ANVS) a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced that CEO Maria Maccecchini, Ph.D., will present at Oppenheimer’s 35th...

ANVS : 1.8000 (-1.64%)
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

ANVS : 1.8000 (-1.64%)
Annovis Bio (NYSE: ANVS) Enrolls First Patients in Phase 3 Alzheimer’s Trial

Annovis Bio (NYSE: ANVS) announced that the first two patients have been enrolled in its pivotal Phase 3 trial evaluating buntanetap for early Alzheimer’s disease. The randomized, placebo-controlled...

ANVS : 1.8000 (-1.64%)
Annovis Bio (NYSE: ANVS) Closes $21M Public Offering to Advance Alzheimer’s Drug Development

Annovis Bio (NYSE: ANVS), a late-stage clinical drug company focused on neurodegenerative diseases, announced the closing of its underwritten public offering, raising $21 million in gross proceeds. The...

ANVS : 1.8000 (-1.64%)
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

ANVS : 1.8000 (-1.64%)
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

ANVS : 1.8000 (-1.64%)

Business Summary

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 1.9933
2nd Resistance Point 1.9467
1st Resistance Point 1.8883
Last Price 1.8000
1st Support Level 1.7833
2nd Support Level 1.7367
3rd Support Level 1.6783

See More

52-Week High 20.0000
Fibonacci 61.8% 12.9425
Fibonacci 50% 10.7625
Fibonacci 38.2% 8.5824
Last Price 1.8000
52-Week Low 1.5250

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals